Seagen

Seagen, previously Seattle Genetics, Inc. is a biotechnology company that engages in the development and commercialization of antibody-based therapies for the treatment of cancer. It hasIts products that include Adcetris and Padcev. It is a company that is advancing a pipeline of novel therapies for solid tumors and blood-related cancers.

As Seattle Genetics expands business globally, its name has been rebranded as Seagen. The company had obtained FDA approvals for two cancer drugs and it partnered with Merck for a Phase II antibody-drug conjugate and a marketed drug.

The company was with a single product in the market, Adcetris (brentuximab vedotin), a drug that got approval in 2011 for Hodgkin’s lymphoma and approved for anaplastic large-cell lymphoma, a type of T-cell non-Hodgkin’s lymphoma. Subsequently, it won approval for its second product, Padcev (enfortumab vedotin-ejfv), for locally advanced or metastatic urothelial cancer, and it received a nod for Tukysa (tucatinib), for HER2-positive breast cancer.

As a pioneer in antibody–drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. Our research team is highly motivated to build an innovative pipeline of transformative cancer therapeutics accelerated by best-in-class technology platforms. Our science is inspired by a singular mission—to make a real difference for people impacted by cancer.

Today, our research efforts are dedicated to advancing a pipeline of:

- Programs using our proprietary ADC technologies

- Novel antibodies and other targeted cancer therapeutics

- New classes of ADC linkers that incorporate novel small molecule payloads to kill tumor cells and induce an anti-tumor immune response

- Novel antibody engineering technologies

- ADCs in combination with checkpoint inhibitors

Science that’s focused on patients first.

At Seagen, we employ rigorous science to discover novel transformational medicines for cancer patients. Our Translational Sciences team acts as the bridge between research and clinical development, innovating in both science and process to accelerate the development of therapies that can make a meaningful difference for patients.

What we learn in the clinic, we leverage to improve future drug design. As a team and an organization, we thrive on scientific challenge and strive to deliver transformational therapies for patients. We’re committed to finding the right drug, for the right patient, at the right dose and schedule, as quickly as possible.

The company rebranded as Seagen in 2020. In September 2020, the company obtained FDA approvals for two cancer drugs and partnered with Merck for a Phase II antibody-drug conjugate and a marketed drug.

Revolutionary technologies with real impact.

Seagen is an industry leader in innovative, targeted drug delivery. ADC technology harnesses the power of potent payloads and the specificity of antibodies to selectively deliver small molecule drugs to tumors. Our proprietary ADC technologies are designed to target cancer cells with greater precision, reducing side effects.

We’re also leveraging our sugar-engineered antibody (SEA)-empowered technology to build a portfolio of proprietary, empowered immuno-oncology agents that can target hematologic malignancies and solid tumors.

The companies product, Adcetris (brentuximab vedotin), received approval in 2011 for Hodgkin’s lymphoma and approved for anaplastic large-cell lymphoma, a type of T-cell non-Hodgkin’s lymphoma. Subsequently, it won approval for its second product, Padcev (enfortumab vedotin-ejfv), for locally advanced or metastatic urothelial cancer, and it received a nod for Tukysa (tucatinib), for HER2-positive breast cancer.